Study Objectives: Obstructive sleep apnea (OSA) is a common sleep disorder. The, literature lacks studies examining sleep, cognition, and Alzheimer's Disease (AD) cerebrospinal fluid (CSF) biomarkers in OSA patients. Therefore, we first studied cognitive performances, polysomnographic sleep, and CSF β-amyloid 42 , tau proteins, and lactate levels in patients affected by subjective cognitive impairment (SCI) divided in three groups: OSA patients (showing an Apnea-Hypopnea Index [AHI] ≥15/hr), controls (showing an AHI < 15/hr), and patients with OSA treated by continuous positive airway pressure (CPAP). Methods: We compared results among 25 OSA, 10 OSA-CPAP, and 15 controls who underwent a protocol counting neuropsychological testing in the morning, 48-hr polysomnography followed by CSF analysis. Results: OSA patients showed lower CSF Aβ 42 concentrations, higher CSF lactate levels, and higher t-tau/Aβ 42 ratio compared to controls and OSA-CPAP patients. OSA patients also showed reduced sleep quality and continuity and lower performances at memory, intelligence, and executive tests than controls and OSA-CPAP patients. We found significant relationships among higher CSF tau proteins levels, sleep impairment, and increased CSF lactate levels in the OSA group. Moreover, lower CSF Aβ 42 levels correlate with memory impairment and nocturnal oxygen saturation parameters in OSA patients. Conclusions: We hypothesize that OSA reducing sleep quality and producing intermittent hypoxia lowers CSF Aβ 42 levels, increases CSF lactate levels, and alters cognitive performances in SCI patients, thus inducing early AD clinical and neuropathological biomarkers changes. Notably, controls as well as OSA-CPAP SCI patients did not show clinical and biochemical AD markers. Therefore, OSA may induce early but possibly CPAP-modifiable AD biomarkers changes.
INTRODUCTION
Obstructive sleep apnea (OSA) is an increasingly common sleep disorder. It is characterized by the occurrence of repetitive episodes of upper airways obstruction leading to apnea and hypopnea events, intermittent hypoxia, oxygen desaturations, and arousals. [1] [2] [3] Apnea is defined as the reduction > 90% of respiratory airflow for 10 or more seconds, while hypopnea is determined by the reduction > 30% of respiratory airflow for 10 or more seconds associated with an oxygen desaturation of ≥3%. 4 Severity of OSA is determined by the frequency of apneas and hypopneas, which constitutes the Apnea-Hypopnea Index (AHI; the sum of all the apneas and hypopneas per hour of sleep). 4 OSA has been currently receiving significant literature attention, since it represents a risk factor for several morbidities. In particular, hypertension is the most frequent comorbidity in patients affected by OSA, since intermittent hypoxia may alter blood pressure and vascular regulation, inducing cardiovascular and cerebrovascular diseases. However, also metabolic disturbances, diabetes, and endothelial dysfunction may be diagnosed in OSA patients who are affected by several metabolic consequences associated with hypoxia. [1] [2] [3] 5, 6 Among them, hypoxia also perturbs cellular functioning increasing the oxidative stress and producing metabolic dysfunction, which are proved conditions promoting neurodegenerative processes, such as Alzheimer's Disease (AD). 7 Measurement of lactate levels may help in diagnosing energy metabolism malfunction and, in particular, mitochondrial dysfunction. 8 In fact, the assessment of cerebrospinal fluid (CSF) lactate levels may display the function of neuronal energy metabolism. 8 Moreover, it has also been demonstrated that lactate changes its cerebral concentrations across the sleep-wake cycles. 9, 10 Literature evidence suggests that OSA is associated with the occurrence of cognitive decline. Consistently, OSA alters cognitive performances (such as memory and attention) by reducing sleep quality and continuity. 11 Moreover, chronic sleep deprivation associated with OSA may promote the accumulation of toxic products inducing neurodegeneration. 12 It has been already proposed a reciprocal link between OSA and AD pathology, as showed by studies demonstrating the relationship between sleep-disordered breathing and cerebral β-amyloid pathology. 13, 14 A few reports have linked OSA and cognition in aging and mild cognitive impairment (MCI) or AD. 13, [15] [16] [17] [18] Accordingly, it was recently demonstrated that OSA reduces the central nervous system (CNS)-derived proteins in the CSF, in particular beta-amyloid (Aβ 42 ) . 19 However, these not-controlled studies lack a design counting the neuropsychological testing and the polysomnographic evaluation investigating sleep structure, immediately followed by CSF analysis.
Subjective cognitive impairment (SCI) is a clinical picture characterized by the occurrence of memory complaints in
Statement of Significance
This study documents that obstructive sleep apnea (OSA) causing intermittent hypoxia and sleep fragmentation may promote Alzheimer's Disease (AD) neurodegeneration in patients affected by subjective cognitive impairment (SCI). Accordingly, SCI patients affected by OSA when compared to SCI controls and OSA patients treated by continuous positive airway pressure (CPAP) showed (i) reduction in CSF Aβ 42 levels and increased lactate concentrations; (ii) reduction in memory, attention, and intelligence performances; and (iii) greater sleep fragmentation, which correlates with higher CSF tau proteins. Therefore, this study first documented that OSA impairs sleep and is associated with clinical and neuropathological biomarkers of AD in SCI patients. patients who do not show cognitive deficits in objective neuropsychological testing. 20 AD pathology may be a cause of SCI, which can represent the preclinical stage of AD, with cognitive decline becoming evident only after long follow-up. 20 Therefore, SCI patients completely meet the expectations for disease-modifying therapeutic strategies.
Based on this background, we aimed to assess in patients affected by OSA and complaining for SCI: (i) CSF AD biomarkers (Aβ 42 and tau proteins) and lactate levels, (ii) sleep architecture measured via polysomnography (PSG), and (iii) cognitive performances. Moreover, we compared PSG, CSF, and neuropsychological data between SCI patients affected by moderate-severe OSA (AHI ≥15), SCI patients considered as controls and showing an AHI < 15, and SCI patients with a previous diagnosis of OSA, which was well treated by continuous positive airway pressure (CPAP) at the time of diagnostic investigations (OSA-CPAP).
METHODS

Participants and Study Design
We consecutively recruited patients affected by SCI admitted to the Sleep Medicine Centre, owing to the Neurology Clinic of the University Hospital of Rome "Tor Vergata". All patients underwent a standard screening including physical and neurological examinations, laboratory tests, neuropsychological testing, PSG, brain magnetic resonance imaging, and lumbar puncture (LP) for CSF biomarkers analysis, counting Aβ 42, total tau (t-tau), phosphorylated-tau (p-tau), and lactate levels assessments.
Patients were considered affected by SCI if they reported subjective memory deficits reflecting a decline over the previous 5 or 10 years, absence of overt cognitive deficits, and cognitive performance in a general normal range. [21] [22] [23] Moreover, patients required to meet the following entry criteria: no concomitant neurologic or psychiatric diseases; no intake of drugs active on the CNS; no intake of melatonin supplements or hypnotics; and no use of caffeine, tobacco, and/or alcohol at the time of the sleep investigations. Exclusion criteria were the following: subclinical seizures and chronic obstructive pulmonary disease; abnormal cell count ( > 4 white cells/mcL) at the CSF sample analysis; and previous diagnosis of sleep disorders other than OSA.
We divided SCI patients in three subgroups: patients with AHI ≥15/h constituted OSA group, patients with AHI < 15/h composed the control group, and patients with a previous diagnosis of OSA, which was well treated by CPAP at the time of diagnostic investigations were included in OSA-CPAP group. In particular, OSA-CPAP patients have to meet three specific inclusion criteria: at least 1 year of CPAP therapy; good compliance to CPAP therapy with a usage of ≥4 hr per night and of > 5 nights per week documented by the ventilator software report; efficacy of the CPAP treatment documented by the ventilator software report (AHI < 5 per hour) and confirmed by the PSG recording.
Therefore, we compared CSF, PSG, and neuropsychological tests among OSA, controls, and OSA-CPAP patients.
Polysomnographic Recording
Patients underwent two consecutive video PSG studies in order to evaluate their nocturnal sleep (SOMNOscreen, SOMNOmedics GmbH, Randersacker, Germany), as already reported. 24 Patients were instructed to maintain the usual sleep schedule and reported it in a sleep diary during the week preceding the evaluation. The first night sleep study was considered an adaptation period. Sleep analysis was performed at the second PSG monitoring according to standard criteria. The following standard parameters were 25 AHI has been defined as the sum of all apneas ( > 90% reduction in airflow for > 10 seconds) and all hypopneas ( > 30% reduction in airflow > 10 s) associated with ≥ 3% O 2 desaturation per hour of sleep. 26 The following oxygen saturation (SaO 2 ) parameters were evaluated: mean SaO 2 , nadir SaO 2 , time spent with SaO 2 < 90% (T < 90), and ODI (number of oxygen desaturations ≥3% per hour). Blinded researchers (CL, FP, AR, and FI) scored PSG recordings on the basis of the international standard criteria of the American Academy of Sleep Medicine. 25, 26 
CSF Collection and Analysis
All the CSF samples were obtained the day after the second PSG recording by LP performed in the decubitus position between 8:00 and 9:30 AM, within 1-2 hr after morning awakening, using an atraumatic needle. We collected CSF samples in polypropylene tubes using standard sterile techniques. The first 4 ml CSF sample was used for biochemistry routine analysis including total cell count and lactate levels. A second 4 ml CSF sample was centrifuged to eliminate cells and cellular debris and immediately frozen at −80°C until the analysis to assess t-tau, p-tau, and Aβ 42 amount. The CSF Aβ 42 , t-tau, and p-tau levels were determined according to previously published standard procedures, using commercially available sandwich enzyme-linked immunosorbent assays (ELISA; Innotest β-Amyloid 1-42, Innotest h-T-tau, Innotest Phospho-T-tau 181; Innogenetics, Ghent, Belgium). 27 Aβ 42 , t-tau, and p-tau were dichotomized on the basis of previously established cutoff values: < 500 pg/mL for Aβ 42 , > 375 pg/mL for t-tau, and > 52 pg/mL for p-tau. [28] [29] [30] The t-tau-Aβ 42 ratio was also calculated, and the cutoff > 0.52 was considered to represent the CSF AD profile. 28 Lactate assay was carried out using commercially available kits following the manufacturer's specifications (Flex reagent cartridge, Dimension Vista System, Siemens Healthcare Diagnostics GmbH, Munich, Germany). 
Neuropsychological Tests
The Mini-Mental State Examination was carried out in all participants within 48 hr of PSG examination. Administration of the neuropsychological battery required approximately 30 min, and scores were corrected for age and education level, as already described.
11 Short-and long-term memory, general intelligence, and executive functions were evaluated.
Short-and Long-Term Memory
-Rey Auditory-Verbal Learning (RAVL) test: A list of 15 words is read to the subject 5 times. Measures include immediate recall (the sum of the words recalled in the five trials, I-RAVL) and a 15-min delayed recall (the number of words recalled 15 min after the last word presentation, D-RAVL).
General Intelligence -Raven's Advanced Progressive Matrices (36 items): A set of three subtests (labeled A, Ab and B) to evaluate nonverbal intelligence, visual processing speed, cognitive speed, and flexibility. It consists in choosing from a set of distractors the item logically missing in a given visual/spatial set.
Executive Functions
-Stroop Color/Word test: Participants are required to name the color ink that a color-word (e.g., RED) is presented in, both in congruent (e.g., when the word RED is printed in red link) and in incongruent conditions (e.g., when the word BLUE is printed in red link). In the latter condition, an increase in the number of errors and the time taken to respond is observed ("Stroop interference effect"). The test is considered the "paradigmatic measure of selective attention". Both total score and Interference score were considered in the analysis.
Data and Statistical Analysis
The study protocol was considered as observational by the Independent Ethical Committee of the University Hospital of Rome "Tor Vergata" and was then performed according to the STROBE statement. An ad hoc database was used to protect personal data. Patients and controls provided their informed consent to the study.
For the statistical analysis, we used a commercial software (Statistica 10.0 program; Statsoft Inc, Tulsa, OK, USA).
The Kolmogorov-Smirnov test was used to check for normal distribution of the obtained PSG and CSF data. All demographical, clinical, PSG, neuropsychological, and CSF data were then compared among the three groups (OSA vs. controls vs. OSA-CPAP) using the one-way analysis of variance. The post hoc analysis was performed using the Tukey test for honestly significant difference. A p value of < .05 was considered to be statistically significant. In OSA, control, and OSA-CPAP groups, correlations between the CSF biomarkers levels, neuropsychological, and PSG data were performed separately by utilizing Pearson's correlation test. Data were analyzed with a significant p value of .05 compensated by the Bonferroni correction for multiple comparisons among total scores.
An additional multiple regression analysis among demographic, clinical, CSF, PSG, and neuropsychological data was also performed.
RESULTS
Demographic and Clinical Data
Sixty-nine consecutive SCI patients were screened from January 2014 to May 2015. Among these patients, 19 presented some exclusion criteria for this study, and thus they were excluded. In particular, 3 had abnormal cell count at CSF analysis, 2 showed subclinical seizures, and 14 reported intake of not admitted drugs. Therefore, 50 SCI patients completely met the eligible criteria and thus were included in the study (Table 1) : 25 patients were included in the OSA group, 15 patients constituted the control group, and 10 patients were included the OSA-CPAP group.
In particular, the 10 SCI patients constituting the OSA-CPAP group showed a mean AHI before CPAP treatment of 33.15 ± 13.72 per hour of sleep and the mean duration of CPAP therapy of 22.90 ± 3.60 months.
Notably, OSA, controls, and OSA-CPAP groups did not differ in terms of age, sex, and MMSE scores. Moreover, the three groups did not differ in terms of body mass index, diagnosis of hypertension, and frequency of apoE4 genotype.
Demographic and clinic data of study participants are reported in Table 1 , while flow-chart is represented in Figure 1 .
CSF Data
Comparing CSF data, we found that OSA patients showed lower CSF Aβ 42 levels with respect to controls and OSA-CPAP patients (p < .001; see Figure 2 ). Conversely, CSF levels of t-tau and p-tau did not differ among the three groups (see Table 1 ). T-tau-Aβ 42 ratio was higher in OSA patients compared to both OSA-CPAP and controls. Moreover, 11 OSA patients, but no patients owing to control or OSA-CPAP groups showed the CSF profile consistent with AD pathology (t-tau-Aβ 42 ratio > 0.52).
Considering OSA patients, CSF Aβ 42 levels were abnormal (below cutoff 500 pg/mL) in 17 (68%) patients, CSF t-tau levels were above cutoff of 375 pg/mL in 6 (24%) patients, and CSF p-tau levels were above the cutoff of 52 pg/mL in 8 (32%) patients. In contrast, controls and OSA-CPAP patients did not show CSF Aβ 42 pathological levels.
Considering CSF lactate levels, we documented significant higher lactate concentrations in OSA patients compared to both controls (p < .001) and OSA-CPAP (p < .001).
All CSF data of OSA, controls, and OSA-CPAP patients are reported in Table 1 .
PSG Data
Comparing PSG parameters among OSA, control, and OSA-CPAP groups, we found reduced SE in OSA patients with respect to both controls (p < .001; Table 2 ) and OSA-CPAP patients (p < .01; Table 2 ). Moreover, OSA patients showed higher WASO than controls (p < .01; Table 2 ). Analyzing the macrostructural sleep parameters, we documented higher N1 in OSA group than both control (p < .001; Table 2 ) and OSA-CPAP (p < .001; Table 2 ) groups. Furthermore, OSA patients showed lower N3 and REM sleep with respect to both controls (p < .01 and p < .001; Table 2 ) and OSA-CPAP patients (p < .01 and p < .001; Table 2 ). OSA patients also showed higher N2 with respect to OSA-CPAP. As expected, in OSA patients higher AHI and ODI with respect to both OSA-CPAP and controls were documented. As concern SaO 2 data, we found in OSA patients reduced mean SaO 2 and nadir SaO 2 associated with higher T < 90 with respect to both OSA-CPAP and controls.
All PSG data are reported in Table 2 .
Neuropsychological Data
According to the diagnosis of SCI in the entire population of patients, we documented scores in a normal range in all the neuropsychological testing performed. However, we found that OSA patients showed lower scores at I-RAVL and D-RAVL with respect to both OSA-CPAP and controls. OSA patients also showed lower scores at Raven test compared to OSA-CPAP. Moreover, OSA patients showed higher Stroop test scores (both total and interference) with respect to OSA-CPAP and controls. Neuropsychological data are reported in Table 3 . 
Correlations Between CSF, Neuropsychological, and PSG Data
Correlating PSG data with CSF Aβ 42 concentrations in the OSA group, we found a significant positive correlation between CSF Aβ 42 levels and mean SaO 2 (R = .62, p = .001; Figure 3) . By comparing CSF t-tau levels and PSG parameters in OSA group, we found the significant correlation between CSF t-tau concentrations and TST (R = −.77, p < .0001; Figure 3 ), SE (R = −.66, p < .001; Figure 3 ), and WASO (R = .60, p = .001; Figure 3 ). Moreover, CSF p-tau levels significantly correlated with TST (R = −.61, p = .001; Figure 3 ), SE (R = −0.66, p < .001; Figure 3 ), and WASO (R = .61, p = .001; Figure 3 ) in OSA patients. Correlating CSF lactate levels with CSF AD biomarkers in OSA group, we documented the significant positive correlation between CSF lactate concentrations and CSF t-tau (R = .55, p < .01) and p-tau levels (R = .58, p < .01). Moreover, CSF lactate levels correlated negatively with SE (R = −.75, p < .0001) and positively with WASO (R = .77, p < .0001).
Analyzing the correlations between neuropsychological tests and CSF biomarkers data, we found the significant positive correlation between CSF Aβ 42 levels and I-RAVL (R = .79, p < .0001), D-RAVL (R = .75, p = 0 < .0001), and Raven (R = .70, p = .0001). Moreover, taking PSG data into account, correlation analysis showed the significant interplay between mean SaO 2 and both I-RAVL (R = .54, p < .01) and D-RAVL (R = .49, p = .01).
The additional multiple regression analysis performed in the OSA group documented the significant mutual interplay between CSF Aβ 42 levels and I-RAVL (β = .88, p < .01), D-RAVL (β = 0.96, p < .0001), and Raven (β = .87, p < .01). Moreover, CSF t-tau levels were correlated in a mutual relationship with CSF lactate levels (β = .87, p < .01), SE (β = −.93, p < .0001), and WASO (β = .91, p < .001), whereas CSF p-tau levels correlated with CSF lactate levels (β = .88, p < .01), SE (β = −.85, p < .01), WASO (β = .87, p < .01), D-RAVL (β = .87, p < .01). Finally, CSF lactate levels were associated with SE (β = .73, p < .05) and WASO (β = .96, p < .0001).
DISCUSSION
This cross-sectional observational study documented that SCI patients affected by OSA show (i) lower CSF Aβ 42 levels which are associated with hypoxia measures and lower scores at memory and intelligence tests; (ii) higher CSF lactate levels which are related to increased WASO and reduced SE; and (iii) higher CSF t-tau and p-tau concentrations which are in a mutual relationship with higher CSF lactate levels and a more significant sleep fragmentation.
In this report, we documented that the diagnosis of OSA is associated with the CSF biomarker profile of preclinical AD in SCI patients. However, SCI patients well treating OSA by CPAP did not show pathological levels of CSF AD biomarkers and lactate, also displaying both the CSF profile and the neuropsychological evaluation not different from the controls.
SCI is actually considered a prodromal stage of AD and may serve as a symptomatic indicator of preclinical AD, representing a pre-MCI condition. 21, 31 Accordingly, SCI is a risk factor for future cognitive decline as well as for MCI and AD. 31 Therefore, SCI condition may identify a target population for interventions at a stage of mild neuronal damage and with still sufficient functional compensation. 31 Furthermore, SCI patients are in a unique position since they are seeking for medical care because of the subjective memory complaints, which make them available for disease-modifying interventions at a time when brain may still be salvageable from AD pathology. 31 AD neuropathology is marked by extracellular amyloid plaques, composed of Aβ 42 peptides, and intracellular neurofibrillary tangles (NFT), containing abnormally hyperphosphorylated tau proteins. 32 In agreement with this evidence, the AD cascade suggests that neurodegeneration starts with the aggregation of insoluble amyloid β-peptides in the SCI stage of AD and is followed in a temporal ordering by hyperphosphorylation and accumulation of tau proteins in NFT. 33, 34 It has been demonstrated that low CSF Aβ 42 levels represent a very strong predictor of AD pathology in patients affected by SCI. 35 However, the tau pathology burden in the SCI stage is not always sufficient to produce increased CSF content of p-tau and t-tau, which reaches pathological concentrations in the MCI stage, where more extensive neurodegeneration occurs. 34 In keeping with this dynamic biomarker view, we documented that SCI patients affected by untreated OSA showed a CSF profile suggestive for preclinical AD, with reduced CSF Aβ 42 levels, and thus possibly presenting an increased risk for developing AD. Moreover, SCI patients affected by moderate-severe OSA showed significantly lower CSF Aβ 42 levels when compared to matched SCI controls. The novelty of this study is the comparison between untreated and CPAP-treated OSA patients. Indeed, SCI patients with a previous diagnosis of OSA, which was well treated by CPAP at the time of the diagnostic investigations, showed higher CSF Aβ 42 levels with respect to SCI patients affected by untreated OSA. Notably, none of the OSA-CPAP patients, but two-thirds of OSA patients, showed pathological CSF Aβ 42 levels ( < 500 pg/mL). Moreover, CSF t-tau and p-tau levels were increased in the 24% and 32% of the OSA group, respectively. However, OSA-CPAP patients and SCI controls did not differ in term of CSF AD biomarkers levels, neuropsychological testing and sleep architecture. These important findings are the first in reporting that OSA patients treated by CPAP are not affected by pathological CSF Aβ 42 concentrations, thus not showing a CSF profile consistent with AD pathology. We also documented that OSA-CPAP patients and SCI controls showed a similar sleep macrostructure, thus confirming that CPAP therapy may restore sleep in OSA patients.
Actually, OSA is a growing health problem increasingly affecting the adult population, which is associated not only with several metabolic and cardiovascular injuries but also with cognitive impairment and brain functional and morphological changes. 11, [36] [37] [38] [39] [40] [41] [42] [43] [44] Hypertension is the most common consequence of OSA and is associated with the predisposition to AD, since it has been demonstrated enhancing Aβ pathology throughout the promotion of the atherosclerotic risk. 45, 46 Hypoxia represents the main candidate in generating hyperthension and atherosclerosis in OSA patients, since it is related to the increased arterial stiffness and cerebrovascular dysfunction, in turn inducing the neuritic plaque formation and NFT lesion densities accumulation. 47 Consistently, hypoxia alters several homeostatic mechanisms by promoting reactive oxygen species production, mithocondrial impairment, atherosclerotic pathology, and neurodegenerative processes.
2,6,7 Increasing literature reports suggest that OSA is not only a frequent diagnosis in AD patients but also raises the risk of developing MCI and AD. 41, 48, 49 However, there is actually no study about sleep and OSA in SCI patients. This study is the first showing that OSA is a frequent diagnosis in SCI patients. Since sleep impairment and OSA may induce the deterioration of cognition due to sleep fragmentation and reduced slow wave sleep and REM sleep, the relationship found in this report between OSA and cognitive complaints in SCI patients may be explained by the sleep architecture impairment. 11, 16, 50 Moreover, OSA-related sleep deprivation and sleep quality reduction may promote AD pathology, taking under consideration the described association between sleep impairment and both β-amyloid and tau proteins cerebral dynamics. 3, 16, [51] [52] [53] [54] [55] In fact, it has been documented that chronic sleep impairment reduces CSF β-amyloid 42 levels inducing preclinical AD in cognitively normal middle-aged individuals. 51 Studies in mouse models of AD confirmed the association between disrupted sleep and AD neurodegeneration, also showing that sleep dysregulation impairs tau metabolism, memory, and synaptic integrity, thus promoting AD pathology. [53] [54] [55] On the other hand, it has been documented that a single night of sleep deprivation increases CSF Aβ 42 levels, abolishing the physiological nighttime reduction in CSF Aβ 42 concentrations. 52 This finding has been related to the previous evidence that during the nighttime sleep, the glymphatic system clears brain extracellular toxic solutes accumulating during wakefulness (like as β-amyloid). 12 Collectively, these findings documented that sleep impairment and nocturnal wakefulness are the main candidates in altering brain β-amyloid and tau proteins dynamics, thus possibly promoting preclinical AD changes.
Therefore, considering that sleep deprivation and nighttime hypoxia may promote both β-amyloid and tau pathology, altering CSF Aβ 42 and tau proteins levels, it is conceivable to speculate that OSA may induce AD pathology in SCI patients through the following possible mechanisms. 3, 12, [53] [54] [55] The first is related to chronic sleep deprivation, which is integral to OSA and may affect the recently demonstrated mechanisms ensuring the cerebral clearance from toxic products accumulating during wakefulness, such as β-amyloid. 12 Moreover, sleep deprivation results in a significant increase in tau pathology, since it represents a chronic stressor inducing the development of AD neurodegeneration. 54, 55 The second is related to nocturnal intermittent hypoxia, present in the OSA condition, which has been demonstrated lowering CSF Aβ 42 concentrations, since it damages enzymes susceptible to hypoxia and responsible for the β-amyloid metabolism. 56, 57 Next, we measured CSF lactate levels in SCI patients. Brain extracellular lactate has been recognized as a reliable sleepwake biomarker due to the changing of its concentrations in relation to metabolic processes. 58 In agreement with this hypothesis, lactate decreases its levels with sleep onset and exhibits a rapid increase in its concentrations during wakefulness. 58 Moreover, lactate, as a product of cellular glucose metabolism, modifies its levels because of both mitochondrial and glycolytic neuronal inefficiency during the AD neurodegeneration. 59 Taking the association between the sleep-wake rhythm dysregulation and AD pathology into account, lactate could be considered either a biomarker of sleep impairment or a biomarker of AD. 8, 58 In keeping with this hypothesis, we documented in SCI patients affected by OSA not only the CSF AD profile but also higher CSF lactate levels, which correlated with both sleep fragmentation and higher CSF biomarkers of neuronal injury (t-tau and p-tau).
Strengths of this study include the assessment of polysomnographic sleep, cognitive performances, and CSF biomarkers in a close temporal ordering. Moreover, the presence of the habituation night of PSG and the inclusion of a broad array of sleep quality measurements increase the implications of this study. However, the main limitation of this report is the inclusion of a small sample of patients due to the strict study design. The second limitation of this study is the recruitment of the patients' populations in a Sleep Medicine Centre and not in a Memory Clinic, thus possibly overestimating sleep-related disturbances in the studied population. However, the recruitment of the present SCI population is in agreement with previous single-center studies.
In conclusion, the relationship between sleep and cognitive decline is a topic of great importance and interest over the past several years, and the data here reported increase the scientific literature on this topic. Accordingly, detecting the earliest signs of AD neurodegeneration is crucial for identification and early treatment of AD and the present results could have important implications. SCI patients are potential candidates for a preventive therapeutic strategy, and studies regarding this preclinical stage of AD are currently encouraged in a public health perspective. Hence, we documented that OSA may be a frequent diagnosis in SCI patients, thus requiring diagnostic investigation in patients complaining for subjective cognitive decline. Moreover, as presently reported, OSA may negatively modulate CSF β-amyloid levels, thus possibly inducing early AD neuropathological changes. Nevertheless, recent studies suggested that changes in CSF Aβ 42 levels precede neuritic β-amyloid plaque deposition, also showing that Aβ 42 levels are reduced in the CSF prior to the deposition of β-amyloid into plaques in the SCI stage of AD. 23, 60 Considering that OSA is a treatable condition possibly representing a risk factor for the reduction of CSF Aβ 42 levels, it is possible to argue that CPAP treatment could stop the ongoing chain of events started with the reduction of CSF Aβ 42 concentrations and leading to abnormal brain deposition of β-amyloid, thus allowing the recover from neurodegenerative processes rescuing brain from OSA-induced AD pathology. However, we are aware that these findings need to be further evaluated in clinical trials assessing CSF AD biomarkers in OSA patients before and after CPAP treatment.
